Results of phase I clinical trials (for example, NCT03473496) have confirmed the relative safety and efficacy of CD38-specific CAR T cells in patients with relapsing and refractory multiple myeloma [96,147,148]. This evidence concerns the gene CD38 and plasma cell myeloma.